Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Review Article
Author Details :
Volume : 7, Issue : 1, Year : 2022
Article Page : 40-43
https://doi.org/10.18231/j.ijcaap.2022.007
Abstract
The world was suffering and People are in great grief due to COVID 19 Pandemic 2020 and 2021 due loss of life, jobs and other related socio-economic issues and now it has been in subsiding mode due to the great weapon COVID vaccine. However omicron is now threatening due to high transmissibility compare to other variants of Corona virus. All of us aware corona Vaccines have been permitted by the regulatory authorities of different countries under emergency situation for restricted use. However by considering Risk-Benefit almost >18 age group most of the people have received the vaccine in few countries but yet to reach out all people in the world. The vaccine has reached the market with exemption category and without detailed exploration of all safety parameters. In the current situation it was learned that most of the corona vaccines are safe and Adverse Events Following Immunization (AEFI) associated with all other vaccines are reported except few serious adverse effects. Corona vaccines are in the verge for administration for all age groups. Hence our health care scientist in the globe needs to study and closely to monitor the Safety parameters of all approved vaccines. This short review highlighted the ADRs reported by WHO approved vaccines during clinical trials and in treatment Adverse Events Following Immunization (AEFI).
Keywords: WHO, SARS–CoV-2, Vaccines
How to cite : Lingadurai S, Mariappan G, Adverse events following immunization (AEFI) for Covid vaccines approved by WHO- A short review. IP Int J Compr Adv Pharmacol 2022;7(1):40-43
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.